# Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

> **NCT01186861** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 205 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

## Interventions

- **DRUG:** OSI-906
- **DRUG:** erlotinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01186861
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-04
- **Primary completion:** 2013-07-01
- **Final completion:** 2015-03-11
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186861, "Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01186861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*